Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.64 |
| ▸ | PI4KA | P42356 | 3/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.59 |
| ▸ | AHCY | P23526 | 3/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28883711 | 1.00 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL20502333 | 1.00 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL1249908 | 0.87 | ADORA2A (0.69) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL10015788 | 0.87 | ADORA2A (0.69) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL19831528 | 0.86 | ADORA2A (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL15045890 | 0.84 | CYP3A4 (0.70) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL28664282 | 0.84 | CYP3A4 (0.65) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL608687 | 0.83 | CYP3A4 (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL15257613 | 0.83 | CYP3A4 (0.68) | ADORA2AADORA1CYP3A4PI4KAPI4K2B | |
| SCHEMBL22131060 | 0.83 | ADORA2A (0.64) | ADORA2AADORA1CYP3A4PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111587107-B | Pharmaceutical composition | 希普拉有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-109384813-B | Preparation method of tenofovir disoproxil fumarate analogue | 广州白云山医药集团股份有限公司白云山制药总厂 | 2021-04-06 | — | — | CN | claimed |
| CN-111587107-A | Pharmaceutical composition | 希普拉有限公司 | 2020-08-25 | — | — | CN | claimed |
| EP-3641733-A1 | PHARMACEUTICAL COMPOSITIONS | Cipla Limited (IN) | 2020-04-29 | — | — | EP | claimed |
| WO-2019021319-A1 | PHARMACEUTICAL COMPOSITIONS | CIPLA LIMITED (IN) | 2019-01-31 | — | — | WO | claimed |
| WO-2019003251-A1 | PHARMACEUTICAL COMPOSITIONS | CIPLA LIMITED (IN) | 2019-01-03 | — | — | WO | claimed |
| US-20240009214-A1 | Method of Treating Viral Infection | CIPLA LIMITED (IN) | 2024-01-11 | — | — | US | disclosed |
| CN-114409706-B | Preparation method of phenyl hydrogen phosphonate and intermediate thereof | 上海医药工业研究院 | 2023-11-28 | — | — | CN | disclosed |
| CN-111836818-B | Phosphoramidate (phosphonate) acetals and phospho (phosphonate) acetal compounds | 纽科利制药公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230310311-A1 | HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY | 2023-10-05 | — | — | US | disclosed |
| CN-116194144-A | Prodrugs of phosphoramide nucleotide analogs and pharmaceutical uses thereof | 吉利德科学公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-111587107-B | Pharmaceutical composition | 希普拉有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-111587107-B | Pharmaceutical composition | 希普拉有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-1923063-A2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080035155-A1 | Topical Antiviral Formulations | GILEAD SCIENCES, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20060234982-A1 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. | 2006-10-19 | — | — | US | disclosed |
| US-20060058265-A1 | Topical antiviral formulations | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | MTAP, TYMP, TYMS | ADORA2A 22/4885ADORA1 11/4885CYP3A4 337/4885 |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | DCTD, MTAP, TYMP | ADORA2A 362/4885ADORA1 183/4885CYP3A4 471/4885 |
| US-20240009214-A1 | Method of Treating Viral Infection | ACE2, ACE, MTAP | ADORA2A 1305/4885ADORA1 991/4885CYP3A4 483/4885 |
| US-20060058265-A1 | Topical antiviral formulations | PNP, TYMP, NT5C2 | ADORA2A 308/4885ADORA1 234/4885CYP3A4 2475/4885 |
| US-20060234982-A1 | Compositions and methods for combination antiviral therapy | TYMS, TYMP, MTAP | ADORA2A 88/4885ADORA1 83/4885CYP3A4 364/4885 |
| US-20230310311-A1 | HYPOTONIC MICROBICIDAL FORMULATIONS AND METHODS OF USE | SI, SAMHD1, VIP | ADORA2A 492/4885ADORA1 290/4885CYP3A4 2156/4885 |
| US-20080035155-A1 | Topical Antiviral Formulations | PNP, TYMP, TK1 | ADORA2A 652/4885ADORA1 264/4885CYP3A4 3344/4885 |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | DCTD, TYMP, MTAP | ADORA2A 463/4885ADORA1 380/4885CYP3A4 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.